EA201792224A1 - Композиции, содержащие ибрутиниб - Google Patents
Композиции, содержащие ибрутинибInfo
- Publication number
- EA201792224A1 EA201792224A1 EA201792224A EA201792224A EA201792224A1 EA 201792224 A1 EA201792224 A1 EA 201792224A1 EA 201792224 A EA201792224 A EA 201792224A EA 201792224 A EA201792224 A EA 201792224A EA 201792224 A1 EA201792224 A1 EA 201792224A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lymphoma
- sodium
- compositions
- ibrutinib
- metabolite
- Prior art date
Links
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 title abstract 4
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 title abstract 4
- 229960001507 ibrutinib Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- 239000002775 capsule Substances 0.000 abstract 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 abstract 2
- 239000002207 metabolite Substances 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 208000003950 B-cell lymphoma Diseases 0.000 abstract 1
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 abstract 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 abstract 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- 239000004376 Sucralose Substances 0.000 abstract 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 abstract 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 abstract 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 239000001768 carboxy methyl cellulose Substances 0.000 abstract 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 abstract 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 1
- 229960002303 citric acid monohydrate Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical class [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 abstract 1
- 201000003444 follicular lymphoma Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 235000019359 magnesium stearate Nutrition 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 201000000050 myeloid neoplasm Diseases 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 abstract 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 abstract 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 abstract 1
- 235000019408 sucralose Nutrition 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/10—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/22—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by pressing in moulds or between rollers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
В настоящем документе обсуждаются фармацевтические композиции, содержащие ибрутиниб, и способы их получения. Эти композиции можно применять при лечении различных состояний, включающих, без ограничений, В-клеточные пролиферативные расстройства, такие как неходжкинская лимфома (диффузная В-крупноклеточная лимфома, фолликулярная лимфома, лимфома из клеток мантийной зоны или лимфома Беркитта), макроглобулинемию Вальденстрема, плазмаклеточную миелому, хронический лимфоцитарный лейкоз, лимфому или лейкоз. Эти композиции предназначены для приема внутрь. Композиции содержатся внутри капсулы, такой как стандартная или вскрываемая капсула, или в жидком составе, таком как суспензия. В одном варианте осуществления фармацевтическая композиция содержит ибрутиниб, его соль, пролекарство или метаболит, микрокристаллическую целлюлозу, кроскармиелиозу натрия, лаурилсульфат натрия и стеарат магния. В другом варианте осуществления фармацевтическая композиция содержит ибрутиниб, его соль, пролекарство или метаболит, микрокристаллическую целлюлозу, натриевую соль карбоксиметилцеллюлозы, гидроксипропилметилцеллюлозу, лимонной кислоты моногидрат, двузамещенный гидрофосфат натрия, сукралозу, метил-пара-гидроксибензоат натрия, этил-пара-гидроксибензоат натрия, концентрированную соляную кислоту, гидроксид натрия и воду.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562143659P | 2015-04-06 | 2015-04-06 | |
| PCT/US2016/026134 WO2016164404A1 (en) | 2015-04-06 | 2016-04-06 | Compositions containing ibrutinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201792224A1 true EA201792224A1 (ru) | 2018-06-29 |
| EA033992B1 EA033992B1 (ru) | 2019-12-17 |
Family
ID=55806788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792224A EA033992B1 (ru) | 2015-04-06 | 2016-04-06 | Композиции, содержащие ибрутиниб |
Country Status (28)
| Country | Link |
|---|---|
| US (5) | US20160287594A1 (ru) |
| EP (3) | EP3280446A1 (ru) |
| JP (3) | JP2018513852A (ru) |
| KR (2) | KR102632745B1 (ru) |
| CN (2) | CN113546054A (ru) |
| AU (3) | AU2016246669B2 (ru) |
| CA (1) | CA2981601A1 (ru) |
| CL (1) | CL2017002512A1 (ru) |
| DK (1) | DK3892302T3 (ru) |
| EA (1) | EA033992B1 (ru) |
| ES (1) | ES2964472T3 (ru) |
| FI (1) | FI3892302T3 (ru) |
| HK (1) | HK1250925A1 (ru) |
| HR (1) | HRP20231207T1 (ru) |
| HU (1) | HUE063751T2 (ru) |
| IL (2) | IL295941A (ru) |
| LT (1) | LT3892302T (ru) |
| MA (2) | MA41901A (ru) |
| MD (1) | MD3892302T2 (ru) |
| MX (2) | MX2017012822A (ru) |
| PH (1) | PH12017501811A1 (ru) |
| PL (1) | PL3892302T3 (ru) |
| PT (1) | PT3892302T (ru) |
| RS (1) | RS64653B1 (ru) |
| SG (2) | SG11201707989PA (ru) |
| SI (1) | SI3892302T1 (ru) |
| UA (1) | UA125681C2 (ru) |
| WO (1) | WO2016164404A1 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2875986C (en) | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| US9545407B2 (en) | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| MD3265084T2 (ro) | 2015-03-03 | 2024-05-31 | Pharmacyclics Llc | Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton |
| US11918684B2 (en) | 2017-03-13 | 2024-03-05 | Liqmeds Worldwide Limited | Pharmaceutical composition of oral suspension of immunosuppressive agents |
| CN108653231A (zh) * | 2017-04-01 | 2018-10-16 | 北京赛林泰医药技术有限公司 | 含有布鲁顿酪氨酸激酶抑制剂的组合物及其制备方法 |
| CN107014943B (zh) * | 2017-06-07 | 2018-08-21 | 福建省微生物研究所 | 一种依鲁替尼对映异构体的检测方法 |
| EP3668508A1 (en) | 2017-08-19 | 2020-06-24 | FTF Pharma Private Limited | An oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
| MA50657A (fr) | 2017-09-26 | 2020-08-05 | Tesaro Inc | Formulations de niraparib |
| WO2019142207A1 (en) * | 2018-01-20 | 2019-07-25 | Natco Pharma Limited | Pharmaceutical compositions comprising ibrutinib |
| KR20190122561A (ko) * | 2018-04-21 | 2019-10-30 | 류형준 | 림프 순환 장애의 치료 또는 경감을 위한 약학적 조성물과 식품 조성물 |
| EA202190045A1 (ru) * | 2018-06-15 | 2021-03-17 | Янссен Фармацевтика Нв | Составы/композиции, содержащие ибрутиниб |
| US20230255885A1 (en) * | 2018-08-18 | 2023-08-17 | Ftf Pharma Private Limited | Chemotherapeutic pharmaceutical suspension for oral dosage |
| US20210308044A1 (en) | 2018-08-18 | 2021-10-07 | Ftf Pharma Private Limited | Pharmaceutical suspension for oral dosage |
| KR102198502B1 (ko) * | 2018-09-16 | 2021-01-05 | 류형준 | 인체의 림프순환 개선을 위한 식품 조성물 |
| CA3120960A1 (en) * | 2018-11-30 | 2020-06-04 | Janssen Biotech, Inc. | Methods of treating follicular lymphoma |
| US10688050B1 (en) | 2018-12-21 | 2020-06-23 | Synthon B.V. | Pharmaceutical composition comprising ibrutinib |
| KR102251435B1 (ko) * | 2020-11-09 | 2021-05-11 | 류형준 | 림프순환 촉진에 의한 부종 개선을 위한 식품 조성물 |
| WO2022260667A1 (en) * | 2021-06-10 | 2022-12-15 | Hikma Pharmaceuticals Usa Inc. | Oral dosage forms of ibrutinib |
| US11433072B1 (en) * | 2021-06-10 | 2022-09-06 | Hikma Pharmaceuticals USA, Inc. | Oral dosage forms of ibrutinib |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2007013467A (es) * | 2005-04-28 | 2008-01-21 | Wyeth Corp | Tanaproget micronizado y composiciones que contienen el mismo. |
| CN102887900B (zh) | 2006-09-22 | 2015-04-29 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
| US8003309B2 (en) | 2008-01-16 | 2011-08-23 | International Business Machines Corporation | Photoresist compositions and methods of use in high index immersion lithography |
| EA031737B1 (ru) | 2010-06-03 | 2019-02-28 | Фармасайкликс, Инк. | Применение ингибиторов тирозинкиназы брутона (btk) для лечения лейкоза и лимфомы |
| EA032463B1 (ru) * | 2011-10-19 | 2019-05-31 | Фармасайкликс Элэлси | Применение ингибиторов тирозинкиназы брутона (втк) |
| CA2875986C (en) * | 2012-06-04 | 2020-06-09 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| WO2014004707A1 (en) * | 2012-06-29 | 2014-01-03 | Principia Biopharma Inc. | Formulations comprising ibrutinib |
| WO2014142678A1 (en) * | 2013-03-14 | 2014-09-18 | Fisher & Paykel Healthcare Limited | Catheter mount with suction port |
| JP6429292B2 (ja) * | 2013-08-12 | 2018-11-28 | ファーマサイクリックス エルエルシー | Ｈｅｒ２増幅性癌の処置のための方法 |
| US9617432B2 (en) * | 2013-08-12 | 2017-04-11 | The Yokohama Rubber Co., Ltd. | Primer composition |
| WO2015071432A1 (en) * | 2013-11-14 | 2015-05-21 | Sandoz Ag | Pharmaceutical compositions of ibrutinib |
| US9545407B2 (en) * | 2014-08-07 | 2017-01-17 | Pharmacyclics Llc | Formulations of a bruton's tyrosine kinase inhibitor |
| CN104523695A (zh) * | 2014-11-12 | 2015-04-22 | 广东东阳光药业有限公司 | 一种治疗过度增生性疾病的药物组合物 |
| CN104407067B (zh) * | 2014-11-17 | 2016-01-20 | 广东东阳光药业有限公司 | 依鲁替尼及其异构体的检测方法 |
| MD3265084T2 (ro) * | 2015-03-03 | 2024-05-31 | Pharmacyclics Llc | Formulări farmaceutice ale inhibitorului tirozin kinazei Bruton |
-
2016
- 2016-04-06 UA UAA201710677A patent/UA125681C2/uk unknown
- 2016-04-06 PT PT211618285T patent/PT3892302T/pt unknown
- 2016-04-06 CA CA2981601A patent/CA2981601A1/en active Pending
- 2016-04-06 HU HUE21161828A patent/HUE063751T2/hu unknown
- 2016-04-06 SG SG11201707989PA patent/SG11201707989PA/en unknown
- 2016-04-06 SG SG10202103458QA patent/SG10202103458QA/en unknown
- 2016-04-06 FI FIEP21161828.5T patent/FI3892302T3/fi active
- 2016-04-06 AU AU2016246669A patent/AU2016246669B2/en active Active
- 2016-04-06 ES ES21161828T patent/ES2964472T3/es active Active
- 2016-04-06 MX MX2017012822A patent/MX2017012822A/es unknown
- 2016-04-06 EP EP16718083.5A patent/EP3280446A1/en not_active Withdrawn
- 2016-04-06 EP EP23194083.4A patent/EP4272835A3/en active Pending
- 2016-04-06 KR KR1020177031664A patent/KR102632745B1/ko active IP Right Grant
- 2016-04-06 PL PL21161828.5T patent/PL3892302T3/pl unknown
- 2016-04-06 EP EP21161828.5A patent/EP3892302B8/en active Active
- 2016-04-06 CN CN202110822502.2A patent/CN113546054A/zh active Pending
- 2016-04-06 MA MA041901A patent/MA41901A/fr unknown
- 2016-04-06 DK DK21161828.5T patent/DK3892302T3/da active
- 2016-04-06 MD MDE20211011T patent/MD3892302T2/ro unknown
- 2016-04-06 EA EA201792224A patent/EA033992B1/ru unknown
- 2016-04-06 RS RS20230820A patent/RS64653B1/sr unknown
- 2016-04-06 MA MA54411A patent/MA54411B1/fr unknown
- 2016-04-06 CN CN201680020815.3A patent/CN107530293A/zh active Pending
- 2016-04-06 US US15/092,195 patent/US20160287594A1/en not_active Abandoned
- 2016-04-06 SI SI201631752T patent/SI3892302T1/sl unknown
- 2016-04-06 IL IL295941A patent/IL295941A/en unknown
- 2016-04-06 LT LTEP21161828.5T patent/LT3892302T/lt unknown
- 2016-04-06 KR KR1020247002178A patent/KR20240013859A/ko not_active Application Discontinuation
- 2016-04-06 JP JP2017552451A patent/JP2018513852A/ja not_active Withdrawn
- 2016-04-06 WO PCT/US2016/026134 patent/WO2016164404A1/en active Application Filing
- 2016-04-06 HR HRP20231207TT patent/HRP20231207T1/hr unknown
-
2017
- 2017-05-23 US US15/602,989 patent/US20170252344A1/en not_active Abandoned
- 2017-09-26 IL IL254695A patent/IL254695B2/en unknown
- 2017-10-02 PH PH12017501811A patent/PH12017501811A1/en unknown
- 2017-10-05 MX MX2021015250A patent/MX2021015250A/es unknown
- 2017-10-05 CL CL2017002512A patent/CL2017002512A1/es unknown
-
2018
- 2018-08-13 HK HK18110381.6A patent/HK1250925A1/zh unknown
-
2019
- 2019-12-10 US US16/708,929 patent/US20200171036A1/en not_active Abandoned
-
2021
- 2021-10-14 AU AU2021250925A patent/AU2021250925B2/en active Active
- 2021-11-08 JP JP2021181761A patent/JP7438178B2/ja active Active
-
2022
- 2022-03-29 US US17/706,783 patent/US20220211713A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/304,685 patent/US20230263804A1/en active Pending
- 2023-11-13 JP JP2023193108A patent/JP2024026087A/ja active Pending
-
2024
- 2024-02-12 AU AU2024200883A patent/AU2024200883A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201792224A1 (ru) | Композиции, содержащие ибрутиниб | |
| MA38399A1 (fr) | Formulation sous forme de comprimé, utile pour traiter l'insuffisance cardiaque aiguë et l'insuffisance cardiaque chronique | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| MX2016008744A (es) | Composiciones farmaceuticas que comprenden azd9291. | |
| MD20160012A2 (ru) | Формулирование SYK ингибиторов | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| PH12017502416A1 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| EA201600088A1 (ru) | Парентеральное введение тапентадола | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| UA113962C2 (xx) | Фармацевтична композиція, яка містить апоморфін як активний інгредієнт | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| MX2015012526A (es) | Inhibodores macrociclicos de cinasa rip2. | |
| GR1008531B (el) | Ποσιμα διαλυματα που περιεχουν υδροχλωρικη ατομοξετινη | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| CA2922375C (en) | Alpha-tea salt forms: compositions and uses for treating disease | |
| EA201992382A2 (ru) | Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения | |
| MX2017015202A (es) | Formulaciones liquidas de celecoxib para administracion oral. | |
| AR092843A1 (es) | Preparacion solida | |
| IN2014DN07897A (ru) | ||
| PL418702A1 (pl) | Kompozycja farmaceutyczna w postaci tabletki zawierająca etenzamid | |
| IN2014MU01179A (ru) | ||
| MX2013012147A (es) | Extracto de pentalinon andrieuxii müeller-argoviensis encapsulado en hidroxietilcelulosa para el tratamiento de la leishmaniasis. | |
| GEP201706747B (en) | Pharmaceutical composition for reducing the trimethylamine n-oxide level | |
| TH154051A (th) | ตัวยับยั้งเซอรีน/ธรีโอนีนไคเนส |